A

argenx

Develops antibody-based therapies for autoimmune diseases

Field Reimbursement Manager

Full-TimePosted on 10/27/2026
$176k - $242k/yr+ Short-term incentive program + Long-term incentive program
Senior
Bachelor's
Milwaukee, WI, USA
RemoteRemote role; candidate must reside in Wisconsin and travel extensively throughout the assigned geography. Candidate must reside in Wisconsin.
Customer Experience & SupportCustomer Success

About the job

Requirements
  • A bachelor's degree or equivalent experience, with 5 or more years of reimbursement, patient access, market access, specialty pharmacy, or related healthcare experience.
  • Demonstrated expertise supporting therapies reimbursed under both medical and pharmacy benefits, including knowledge of Medicare, Medicaid, commercial insurance, prior authorizations, claims, appeals, and patient access pathways.
  • Ability to build productive relationships with healthcare providers and office staff.
  • Strong communication, presentation, organizational, problem-solving, and customer engagement skills.
  • Ability to work independently and collaborate across cross-functional teams to drive patient access solutions and business objectives.
  • Willingness and ability to travel extensively throughout the assigned geography.
Responsibilities
  • Serve as the primary reimbursement and patient access resource for healthcare providers and staff within the assigned territory, building trusted relationships through in-person and virtual engagement.
  • Educate customers on patient access, reimbursement, coverage policies, prior authorizations, claims, appeals, billing and coding considerations, specialty pharmacy processes, and available patient support resources.
  • Develop account-specific access strategies, provide guidance on reimbursement challenges, and help providers navigate access barriers in accordance with company policy.
  • Manage complex reimbursement issues and escalations with urgency and professionalism while sharing customer insights and payer trends to inform business strategy and improve the provider and patient experience.
  • Partner with Patient Services, Case Management, Market Head, Business Leader, Market Access, and other stakeholders to address access barriers, coordinate account strategies, and deliver a consistent customer experience.
  • Participate in case reviews, escalation management, and ongoing collaboration to support timely patient access and organizational learning.
  • Develop and execute territory plans aligned with customer needs, business priorities, and access objectives.
  • Utilize CRM tools, data analytics, and reporting to document activities, identify opportunities, track performance, and effectively manage territory priorities and travel.
  • Demonstrate a proactive, solutions-oriented approach to addressing patient access challenges.
  • Navigate complex account dynamics, manage conflict constructively, and collaborate effectively to achieve positive outcomes for patients, providers, and the organization.
  • Conduct all activities in full compliance with applicable laws, regulations, company policies, and argenx values.
Desired Qualifications
  • Experience in neurology, immunology, rare disease, specialty biologics, or other complex specialty therapeutic areas.
  • Knowledge of buy-and-bill and specialty pharmacy distribution models, infusion reimbursement, site-of-care optimization, and payer management strategies.
  • Demonstrated success in highly collaborative environments, utilizing CRM systems, data analytics, and customer insights to inform account strategy and engagement.

About the company

A

argenx

View
Website

argenx develops and markets antibody-based therapies for severe autoimmune diseases. Its medicines work by modulating the immune system through engineered antibodies, notably efgartigimod (VYVGART for generalized myasthenia gravis and VYVGART Hytrulo for CIDP) that influence FcRn pathways. The company differentiates itself through antibody engineering capabilities and a co-creation model with academic and industry partners, plus a pipeline focused on FcRn-, complement-, and target-directed programs across autoimmune indications. Its goal is to provide effective antibody medicines that improve patient outcomes and expand global access through its development and commercial footprint.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Amsterdam, Netherlands

Founded

2008

Get referred to argenx

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • May 8, 2026 FDA approval opened VYVGART to all adult gMG serotypes.
  • August 17, 2026 ALKIVIA met primary endpoint in autoimmune myositis, adding a multibillion-dollar indication.
  • September 29, 2026 AANEM data extended VYVGART into ocular MG and longer-duration CIDP use.

What critics are saying

  • UCB's RYSTIGGO and J&J's nipocalimab attack the same FcRn market by 2027.
  • VYVGART concentration remains extreme; one franchise drove $2.8 billion first-half 2026 sales.
  • If ALKIVIA or upcoming myositis filings disappoint, argenx loses its next blockbuster expansion.

What makes argenx unique

  • VYVGART is first-and-only approved for all adult gMG serotypes after May 8, 2026.
  • argenx scaled $1.5 billion Q2 2026 product sales with 60% year-over-year growth.
  • August 27, 2026 Forte acquisition added FB102, broadening the immunology pipeline.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 24th, 2026
Argenx Q3 sales jump to $1.7B, but net margin slips to 31.7% as costs climb

Argenx reported third-quarter 2026 revenue of $1,751 million, up from $1,151 million a year earlier. Net income rose to $506 million from $344 million, and basic earnings per share reached $8.07, against $5.61. The stock closed at €782.2 on October 23, roughly flat on the week. Trailing net margin fell to 31.7% from 41.6%. Operating margin was 28%, or 37% excluding costs tied to the Forte acquisition. The quarter included $150 million of transaction charges. Combined research and development and administrative spending is expected to reach about $4 billion in 2026, up roughly 45% from 2025. VYVGART still drives sales. The company is also advancing FB102, which has positive Phase 2 celiac data, and empasiprubart, which faces a registrational readout in December 2026.

Yahoo Finance
Oct 23rd, 2026
argenx Q3 sales jump 54% to $1.7B as pipeline expands and operating profit hits $486M

argenx reported $1.7 billion in product sales for the third quarter of 2026, up 54% year over year and 13% quarter over quarter. The company discussed the results on an earnings call on October 22, 2026. Growth came from wider use of VYVGART in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Operating profit reached $486 million, as revenue gains covered higher research and development costs. argenx is advancing 10 clinical-stage molecules. They include empasiprubart for multifocal motor neuropathy, which is heading toward its first phase 3 readout, and FB102 for celiac disease, which had positive phase 2 results. The company prepares for up to five potential launches in 2027 as part of its Vision 2030 plan.

BitRss
Oct 22nd, 2026
Argenx SE (ARGX) Stock: Falls Despite $1.7 Billion Sales and Profit Growth

Blockonomi 1 day ago 129 Tldr. * ARGX slips 1.00% as blockbuster VYVGART sales reach $1.7 billion in Q3 2026. * Argenx profit climbs to $506 million, but ARGX shares still face selling pressure. * VYVGART sales jump 54% year over year as Argenx expands its treatment pipeline. * Rising development costs push Argenx quarterly operating expenses to $1.27B. * December empasiprubart results could mark Argenx's next major clinical milestone. Argenx SE (ARGX) shares fell despite stronger third-quarter sales and higher profit. The stock declined 1.00% to $881.15, losing $8.90 during trading. Shares recovered from early lows before renewed selling emerged near $890 during a volatile session. argenx SE, ARGX VYVGART drives strong quarterly sales. Argenx reported $1.72 billion in third-quarter product sales, up 54% from last year. Sales rose 13% sequentially as demand grew across major treatment areas. The company markets VYVGART for autoimmune conditions, including generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Total operating income reached $1.75 billion, against $1.15 billion one year earlier. Quarterly operating profit rose to $486 million from $346 million in the comparable period. Net profit increased to $506 million from $344 million, while basic earnings reached $8.07 per share. Nine-month VYVGART sales totaled $4.53 billion versus $2.87 billion a year earlier. Operating profit doubled to $1.37 billion, reflecting stronger commercial activity over nine months. However, the company increased spending to support development, marketing, and operations. Rising expenses offset part of growth. Third-quarter operating expenses climbed to $1.27 billion from $805 million a year earlier. Research and development costs increased to $503 million as argenx advanced clinical programs across multiple diseases. Selling, general and administrative expenses reached $598 million, compared with $336 million last year. Administrative spending included approximately $150 million in costs related to the Forte Biosciences acquisition. Argenx paid about $2.1 billion for that transaction, net of acquired cash. Combined cash and current financial assets totaled $3.7 billion in September, down from $4.4 billion in December. Argenx now expects combined research, development, and administrative expenses near $4 billion for 2026. That estimate includes Forte acquisition costs and ongoing commercial expansion. The updated forecast reflects spending on its pipeline alongside VYVGART sales growth worldwide. Drug pipeline sets up coming milestones. Argenx submitted an FDA application to expand VYVGART treatment into ocular myasthenia gravis. The FDA also granted priority review for pediatric generalized myasthenia gravis, targeting February 2027. Additionally, argenx expects a VYVGART Hytrulo autoinjector launch during the second half of 2027. Positive Phase 3 ALKIVIA results supported further development in immune-mediated muscle diseases. Argenx expects an application for immune-mediated necrotizing myopathy before year-end 2026. Meanwhile, its empasiprubart Phase 3 study in multifocal motor neuropathy should report results in December. The company plans Phase 3 development for FB102 in celiac disease following promising earlier results. Its Vision 2030 targets 50,000 treated patients, 10 approved indications, and five candidates in registrational development. Despite sales growth and clinical progress, ARGX shares faced continued selling pressure. The post Argenx SE (ARGX) stock: falls despite $1.7 billion sales and profit growth appeared first on blockonomi. BitRss shares this Content always with License. Screenshot generated in real time with SneakPeek Suite * homepage * flash news * Argenx SE (ARGX) stock: falls despite $1.7 billion sales and profit growth.

Kooc Media Ltd.
Oct 22nd, 2026
Argenx SE (ARGX) stock: falls despite $1.7 billion sales and profit growth.

Argenx SE (ARGX) stock: falls despite $1.7 billion sales and profit growth. Stronger VYVGART sales and earnings fail to lift ARGX as expenses rise and drug trials advance. Tldr. Table of Contents * ARGX slips 1.00% as blockbuster VYVGART sales reach $1.7 billion in Q3 2026. * Argenx profit climbs to $506 million, but ARGX shares still face selling pressure. * VYVGART sales jump 54% year over year as Argenx expands its treatment pipeline. * Rising development costs push Argenx quarterly operating expenses to $1.27B. * December empasiprubart results could mark Argenx's next major clinical milestone. Argenx SE (ARGX) shares fell despite stronger third-quarter sales and higher profit. The stock declined 1.00% to $881.15, losing $8.90 during trading. Shares recovered from early lows before renewed selling emerged near $890 during a volatile session. VYVGART drives strong quarterly sales. Argenx reported $1.72 billion in third-quarter product sales, up 54% from last year. Sales rose 13% sequentially as demand grew across major treatment areas. The company markets VYVGART for autoimmune conditions, including generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Total operating income reached $1.75 billion, against $1.15 billion one year earlier. Quarterly operating profit rose to $486 million from $346 million in the comparable period. Net profit increased to $506 million from $344 million, while basic earnings reached $8.07 per share. Nine-month VYVGART sales totaled $4.53 billion versus $2.87 billion a year earlier. Operating profit doubled to $1.37 billion, reflecting stronger commercial activity over nine months. However, the company increased spending to support development, marketing, and operations. Rising expenses offset part of growth. Third-quarter operating expenses climbed to $1.27 billion from $805 million a year earlier. Research and development costs increased to $503 million as argenx advanced clinical programs across multiple diseases. Selling, general and administrative expenses reached $598 million, compared with $336 million last year. Administrative spending included approximately $150 million in costs related to the Forte Biosciences acquisition. Argenx paid about $2.1 billion for that transaction, net of acquired cash. Combined cash and current financial assets totaled $3.7 billion in September, down from $4.4 billion in December. Argenx now expects combined research, development, and administrative expenses near $4 billion for 2026. That estimate includes Forte acquisition costs and ongoing commercial expansion. The updated forecast reflects spending on its pipeline alongside VYVGART sales growth worldwide. Drug pipeline sets up coming milestones. Argenx submitted an FDA application to expand VYVGART treatment into ocular myasthenia gravis. The FDA also granted priority review for pediatric generalized myasthenia gravis, targeting February 2027. Additionally, argenx expects a VYVGART Hytrulo autoinjector launch during the second half of 2027. Positive Phase 3 ALKIVIA results supported further development in immune-mediated muscle diseases. Argenx expects an application for immune-mediated necrotizing myopathy before year-end 2026. Meanwhile, its empasiprubart Phase 3 study in multifocal motor neuropathy should report results in December. The company plans Phase 3 development for FB102 in celiac disease following promising earlier results. Its Vision 2030 targets 50,000 treated patients, 10 approved indications, and five candidates in registrational development. Despite sales growth and clinical progress, ARGX shares faced continued selling pressure. Limited Time Offer Get 3 free stock ebooks. Discover top-performing stocks in AI, Crypto, and Technology with expert analysis. * Top 10 AI Stocks - Leading AI companies * Top 10 Crypto Stocks - Blockchain leaders * Top 10 Tech Stocks - Tech giants

Yahoo Finance
Oct 22nd, 2026
argenx Q3 sales jump 54% to $1.7B as VYVGART demand grows, with up to five 2027 launches planned

argenx reported third-quarter product net sales of $1.7 billion, up 54% from a year earlier and 13% from the previous quarter. Demand for its drug VYVGART kept growing in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Operating profit was $486 million, a 28% margin, or 37% excluding $150 million in costs from the Forte acquisition. The company ended the quarter with $3.7 billion in cash and current financial assets after paying a net $2.1 billion for Forte. argenx plans to file for VYVGART approval in immune-mediated necrotizing myopathy by year-end. It could have up to five US launches in 2027. It expects combined research and development and selling, general and administrative expenses of about $4 billion for 2026, and is moving Forte's FB-102 into Phase III for celiac disease.